Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NNVC Nanoviricides Inc
- Stocks
- Healthcare
- NYSEAMERICAN: NNVC
Price (delayed)
$1.39
Market cap
$22.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.7
Enterprise value
$19.8M
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped
Highlights
The EPS has grown by 15% YoY and by 2.8% from the previous quarter
NNVC's quick ratio is down by 47% year-on-year and by 37% since the previous quarter
The equity has declined by 17% year-on-year and by 15% since the previous quarter
Key stats
What are the main financial stats of NNVC
Market
Valuations
Earnings
Shares outstanding
16.07M
Market cap
$22.34M
Enterprise value
$19.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.46
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$9.87M
Net income
-$9.73M
EBIT
-$9.73M
EBITDA
-$8.95M
Free cash flow
-$8.4M
Per share
Balance sheet
Liquidity
EPS
-$0.7
EPS diluted
-$0.7
Free cash flow per share
-$0.52
Book value per share
$0.56
Revenue per share
$0
TBVPS
$0.61
Total assets
$10.03M
Total liabilities
$1.2M
Debt
$0
Equity
$8.83M
Working capital
$1.53M
Debt to equity
0
Current ratio
2.27
Quick ratio
2.12
Net debt/EBITDA
0.28
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-84.3%
Return on equity
-95.4%
Return on invested capital
-160.1%
Return on capital employed
-110.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NNVC stock price
How has the Nanoviricides stock price performed over time
Intraday
13.01%
1 week
-2.8%
1 month
-18.71%
1 year
-19.65%
YTD
-2.8%
QTD
18.8%
Financial performance
How have Nanoviricides's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.87M
Net income
-$9.73M
Gross margin
N/A
Net margin
N/A
Nanoviricides's operating income has decreased by 3.6% QoQ
NNVC's net income is down by 3.9% QoQ and by 2.3% YoY
Price vs fundamentals
How does NNVC's price correlate with its fundamentals
Growth
What is Nanoviricides's growth rate over time
Valuation
What is Nanoviricides stock price valuation
P/E
N/A
P/B
2.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 15% YoY and by 2.8% from the previous quarter
The stock's price to book (P/B) is 56% more than its 5-year quarterly average of 1.4 and 9% more than its last 4 quarters average of 2.0
The equity has declined by 17% year-on-year and by 15% since the previous quarter
Efficiency
How efficient is Nanoviricides business performance
Nanoviricides's return on invested capital has decreased by 29% YoY and by 8% QoQ
Nanoviricides's return on equity has decreased by 28% YoY and by 9% QoQ
NNVC's return on assets is down by 27% year-on-year and by 7% since the previous quarter
Dividends
What is NNVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NNVC.
Financial health
How did Nanoviricides financials performed over time
NNVC's quick ratio is down by 47% year-on-year and by 37% since the previous quarter
NNVC's total liabilities is up by 47% YoY
NNVC's debt is 100% lower than its equity
The equity has declined by 17% year-on-year and by 15% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.